Over a lifetime, 1 out of 7 men will receive a diagnosis of prostate cancer. Although most patients present with localized or indolent disease, there are still a big proportion of patients that will eventually progress to metastatic prostate cancer, for which no curative treatment currently ...
177Lu-PSMA therapy : Current evidence for use in the treatment of patients with metastatic prostate cancer BACKGROUND: Despite significant progress in the treatment of metastatic castration-resistant prostate cancer (mCRPC) in recent years (including agents targeting androgen receptor signaling, chemotherap...
(lutetium Lu 177 vipivotide tetraxetan) (formerly referred to as 177Lu-PSMA-617) for the treatment of adult patients with a certain type of advanced cancer called prostate-specific membrane antigen-positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has ...
Pluvicto™ (lutetium Lu 177 vipivotide tetraxetan) is a radiopharmaceutical used to treat adults with an advanced cancer called prostate-specific membrane antigen–positive metastatic castration-resistant prostate cancer (PSMA-positive mCRPC) that has spread to other parts of the body ...
Lutetium-177(177Lu)鈥揚SMA-617 has been approved for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Our main objective is to elucidate the association between177Lu-PSMA-617 and reported adverse events (AEs) in the FDA Adverse Event Reporting System (FAERS) database. ...
Today's standard treatment of advanced-stage ovarian cancer, including surgery followed by a paclitaxel-platinum-based chemotherapy, is limited in efficacy. Recently, we could show that radioimmunotherapy (RIT) with 177Lu-labelled anti-L1 cell adhesion molecule (L1CAM) monoclonal antibody chCE7 is ...
Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy. J Med Radiat Sci. 2017;64(1):52-60.Emmett, L., Willowson, K., Violet, J., Shin, J., Blanksby, A., and Lee, J. (2017) Lutetium...
e17057#Background:Results from the VISION trial (NCT03511664) led to the approval of lutetium-177 (177Lu)鈥揚SMA-617 for the treatment of metastatic castration-resistant prostate cancer (mCRPC). This trial excluded patients with baseline cytopenias, thus safety in this frequently encountered ...
The objective of this study was to analyze the safety and efficacy of (177)Lu-labeled DOTAGA-based prostate specific membrane antigen (PSMA) ligand (177)Lu-DOTAGA-(I-y)fk(Sub-KuE) ((177)Lu-PSMA) in patients with metastatic castration-resistant prostate cancer (mCRPC). Fifty-six mCRPC pa...
[177Lu]Lu-PSMARadioligand therapyCastration-resistant prostate cancerRadioligand therapie met lutetium-177 prostaat specifiek membraan antigeen ([ 177 Lu]Lu-PSMA) lijkt een veelbelovende behandeling voor gemetastaseerde, castratieresistente prostaatkankerpatinten. In dit overzichtsartikel wordt de ...